Answers are grounded in this paper and cite their sources.
This study provides clinically and preclinically actionable insights into the biology of PFA recurrence. The hypomethylation predisposition signature in PFA is a potential risk-classifier for trial stratification. We show that the cellular heterogeneity of PFAs evolves largely because of genetic evolution of neoplastic cells.
No takes yet. Share an insight, caveat, or question.
Donson et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: